恶性胶质瘤PD-1抑制剂免疫治疗与立体定向放射外科最佳时序:倾向评分匹配多中心队列研究
该回顾性多中心队列研究基于TriNetX数据库(2005-2022)纳入接受SRS及至少一次PD-1抑制剂治疗的成人恶性胶质瘤患者,按PD-1抑制在SRS前8周(pre-SRS)与SRS后(post-SRS)分层并行1:1倾向评分匹配。匹配后每组233例,pre-SRS组认知障碍、颅神经缺陷及死亡的比值显著升高,Kaplan-Meier分析证实风险增加,提示SRS前使用PD-1抑制剂与更多神经功能缺陷及更低生存相关。
要点
- SRS前8周内使用PD-1抑制剂与认知障碍风险升高相关(OR 1.75)。
- SRS前使用PD-1抑制剂与颅神经缺陷风险升高相关(OR 2.00)。
- SRS前使用PD-1抑制剂与死亡风险升高相关(OR 1.53)。
核心结论
- SRS前使用PD-1抑制剂与更多神经功能缺陷及更低生存相关。
- 需前瞻性研究确定恶性胶质瘤中SRS与免疫治疗的最佳时序。
研究设计与样本
- 回顾性多中心倾向评分匹配队列研究,使用TriNetX研究网络数据库(2005-2022)。
- 纳入接受SRS及至少一次PD-1抑制剂治疗的成人恶性胶质瘤患者。
- 按PD-1抑制在SRS前8周(pre-SRS)与SRS后(post-SRS)分层,1:1倾向评分匹配后每组233例。
主要发现
- 匹配前pre-SRS组(n=429)与post-SRS组(n=381)在性别、族裔、种族、超重/肥胖、2型糖尿病、血脂异常、抗凝药使用、度伐利尤单抗及阿替利珠单抗使用上差异显著(均p<0.05)。
- 匹配后除年龄(均值63.50[SD 11.84]岁 vs 63.36[SD 10.82]岁,p=0.012)和替西木单抗使用(n=0[0%] vs n≤10[≤4.29%],p=0.001)外,基线特征无显著差异。
- 匹配后pre-SRS组认知障碍(OR 1.75,95%CI 1.04-2.98,p=0.034)、颅神经缺陷(OR 2.00,95%CI 1.11-3.69,p=0.021)及死亡(OR 1.53,95%CI 1.06-2.20,p=0.023)风险显著升高。
- 行为/情绪改变(OR 0.91,p=0.726)、步态/协调障碍(OR 1.28,p=0.421)、出血并发症(OR 0.97,p=0.930)、运动缺陷(OR 0.86,p=0.590)、癫痫发作(OR 0.99,p=0.971)及感觉障碍(OR 0.91,p=0.737)无显著差异。
- Kaplan-Meier分析证实pre-SRS组认知障碍(p=0.0076)、颅神经缺陷(p=0.0104)及死亡(p=0.0109)风险升高。
临床怎么用
- 对于拟接受SRS的恶性胶质瘤患者,应审慎评估SRS前8周内使用PD-1抑制剂的时序安排。
- 治疗决策时需权衡SRS前免疫治疗可能带来的认知障碍、颅神经缺陷及死亡风险升高。
局限性
- 回顾性研究设计,存在数据库编码及未测量混杂的潜在偏倚。
- 匹配后年龄及替西木单抗使用仍存在显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal order of treatment with programmed cell death protein 1 (PD-1) inhibitor immunotherapy and stereotactic radiosurgery (SRS) in malignant gliomas remains unclear. This study examined whether the timing of PD-1 inhibitor administration relative to SRS affects patient neurological outcomes and survival in a multi-institutional propensity score-matched cohort. METHODS: A retrospective analysis was conducted using the TriNetX Research Network database (2005-2022), identifying adults with malignant gliomas who received SRS and at least one PD-1 inhibitor. Patients were stratified into two cohorts based on whether PD-1 inhibition occurred 8 weeks before SRS (pre-SRS) versus after SRS (post-SRS). Propensity score matching (1:1) was performed for demographics, comorbidities, and relevant medications. Clinical outcomes, including mortality, cognitive impairments, cranial nerve deficits, seizures, hemorrhagic complications, and functional impairments, were assessed over a 3-year follow-up period. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and Kaplan-Meier (KM) survival analyses were used to compare cumulative incidence rates. RESULTS: Before matching, the pre-SRS (n = 429) versus post-SRS (n = 381) cohorts differed significantly in sex (female, unknown), ethnicity (Hispanic/Latino, unknown), race (Asian, American Indian, other), overweight/obesity, type 2 diabetes mellitus, lipidemia, anticoagulant use, durvalumab use, and atezolizumab use (all p < 0.05). After propensity score matching (n = 233 per group), PD-1 inhibition pre- versus post-SRS showed no significant differences in baseline characteristics except for age (mean 63.50 [SD 11.84] years vs 63.36 [SD 10.82] years, p = 0.012) and tremelimumab use (n = 0 [0%] vs n = ≤ 10 [≤ 4.29%], p = 0.001). In propensity score-matched patients, PD-1 inhibitor use before SRS was associated with significantly higher odds of cognitive impairments (OR 1.75, 95% CI 1.04-2.98, p = 0.034), cranial nerve deficits (OR 2.00, 95% CI 1.11-3.69, p = 0.021), and mortality (OR 1.53, 95% CI 1.06-2.20, p = 0.023), while other outcomes including behavioral/mood changes (OR 0.91, p = 0.726), gait/coordination disorders (OR 1.28, p = 0.421), hemorrhagic complications (OR 0.97, p = 0.930), motor deficits (OR 0.86, p = 0.590), seizures/epilepsy (OR 0.99, p = 0.971), and sensory disturbances (OR 0.91, p = 0.737) showed no significant differences. KM analyses confirmed elevated risks of cognitive impairment (p = 0.0076), cranial nerve deficits (p = 0.0104), and mortality (p = 0.0109) in the pre-SRS group. CONCLUSIONS: Pre-SRS PD-1 inhibitor use was associated with more neurological deficits and lower survival, highlighting the need for prospective studies on optimal SRS immunotherapy timing in malignant gliomas.
引用
- O'Leary S, Fu AY, Rogers VA, et al. Optimal timing of PD-1 inhibitor immunotherapy administration to stereotactic radiosurgery in malignant gliomas: a propensity score-matched multi-institutional cohort study. J Neurosurg. 2026. PMID: 42139726. doi:10.3171/2025.12.JNS252327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。